Fennec Pharmaceuticals
FENC
45 hedge funds and large institutions have $98.1M invested in Fennec Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 9 increasing their positions, 2 reducing their positions, and 4 closing their positions.
575% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 4
350% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 2
105% more funds holding
Funds holding: 22 → 45 (+23)
6% more capital invested
Capital invested by funds: $92.2M → $98.1M (+$5.9M)
2.89% more ownership
Funds ownership: 47.89% → 50.77% (+2.9%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$8.89M |
| 2 |
BlackRock
New York
|
+$6.58M |
| 3 |
State Street
Boston,
Massachusetts
|
+$1.76M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$1.2M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$854K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.12M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$686K |
| 3 |
Renaissance Technologies
New York
|
-$421K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$114K |
| 5 |
Goldman Sachs
New York
|
-$11.9K |
FENC Hedge Fund Activity: Q2 2018 in Review
45 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q2 2018, worth a combined $98.1M — up 6.4% from $92.2M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new FENC positions and 4 closed out — a net gain of 23 holders — while 9 added to existing stakes and 2 trimmed.
The largest buyer was Avoro Capital Advisors, adding an estimated $8.89M. The largest seller was Millennium Management, exiting entirely with an estimated $1.12M sold.
- 45 institutional investors held Fennec Pharmaceuticals (FENC) as of Q2 2018, up from 22 in Q1 2018.
- Funds reported $98.1M of Fennec Pharmaceuticals stock for Q2 2018, up 6.4% quarter-over-quarter.
- 27 funds opened new Fennec Pharmaceuticals positions in Q2 2018 and 4 closed out, a net change of +23 holders.
- The largest Fennec Pharmaceuticals buyer in Q2 2018 was Avoro Capital Advisors, an estimated $8.89M added.
- The largest Fennec Pharmaceuticals seller in Q2 2018 was Millennium Management, an estimated $1.12M sold.
Based on aggregated 13F filings for Q2 2018.